NUE 20798
Alternative Names: NUE-20798Latest Information Update: 28 Jun 2023
Price :
$50 *
At a glance
- Originator Nuevolution
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action BRD1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Atopic-dermatitis in Denmark (PO)
- 30 Jul 2019 Nuevolution has been acquired by Amgen
- 03 Jun 2019 NUE 20798 is available for licensing as of 31 May 2019. http://nuevolution.com/partnering/drug-discovery-partnerships/ (Nuevolution pipeline, May 2019)